NTII - Miscellaneous Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTII - Miscellaneous

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (1117)	1/15/2005 3:05:27 PM
From: John McCarthy	of 1296

2004 - Dec 28th AXYX Axonyx Completes Phenserine Trial Tuesday December 28, 10:26 am ET Axonyx Completes Phenserine Clinical Trial for Alzheimer's Treatment NEW YORK (AP) -- Biopharmaceutical company Axonyx Inc. reported Tuesday that it completed the last treatment period for its Alzheimer's disease drug candidate Phenserine in late stage clinical trials. Shares of Axonyx rose 35 cents, or 5.7 percent, to $6.45 in morning trading on the Nasdaq. The company said it plans to spend the next several weeks analyzing data from the Phase III clinical trial and report study results by March. The study enrolled more than 375 Alzheimer's patients who were either treated with 15 milligrams of Phenserine twice a day, or 10 milligrams of Phenserine twice a day or placebo, and then given standard memory and cognition tests. The trial started in June 2003. Phenserine is an enzyme and inhibitor being developed to treat patients with mild-to-moderate Alzheimer's disease. The company said two additional Phase III clinical trials were initiated for the treatment in the second half of 2004.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next